Deve Dikeni (Silybum Marianum)
Özet
Süt deve dikeni olarak silyum marianum kanser, hepatit, safra yolu hastalıkları gibi birçok hastalığın tedavisinde çok uzun zamandır kullanılmaktadır. Aktif metaboliti silymarin kanser riski yüksek olan grupta kanserden korunmak amacı ile kullanılabilir. Deve dikeni ve silymarin karaciğer, prostat, kolon, pankreas kanserinde tamamlayıcı tedavi olarak kullanılmıştır. Silymarin kanser hücresinde apopitozu artırarak ve serbest okisjen radikal oluşuma engel olarak etki gösterir. Silymarinin kanser önleyici etkisi ve son zamanlarda insanların kemoterapiden daha fazla bitkisel tedaviye merak etmesi nedeni ile deve dikenine ilgi artmıştır. Bu bölümde deve dikeni ile ilgili makaleler, ilaç etkileşimi detaylı anlatılacaktır.
As milk thistle, silyum marianum has been used for a long time in the treatment of many diseases such as cancer, hepatit, biliary truct diseases. Its active metabolite,silymarin, can be used to protect aganist cancer in groups with high cancer risk.Milk thistle and silymarin have been used complementary therapy in liver, prostate, colon and pancreatic cancer. silymarin acts by increasing apopitosiz in cancer cells and preventing free oxygen radical formation. The value of milk thistle has increased due to the anti-cancer effect of silymarin and the fact that people are more interested in herbal medicine than cheometherapy. In this chapter, articles about milk thistle and its drug interactions will be explained in detail.
Referanslar
Angeli JP, Barcelos GR, Serpeloni JM, Barbosa F, Jr., Nersesyan A, Mantovani MS. Evaluation of the genotoxic and anti-genotoxic activities of silybin in human hepatoma cells (HepG2). Mutagenesis 2010; 25: 223-229.
Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, et al. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol 2016; 12: 1929-1946. 4. Anwar S, Madkor HR, Ahmed N, Wagih
Barros TMB, Lima APB, Almeida TC, da Silva GN. Inhibition of urinary bladder cancer cell proliferation by silibinin. Environ Mol Mutagen 2020; 61: 445-455.
Bhatia N, Agarwal C, Agarwal R. Differential responses of skin cancer-chemopreventive agents silibinin, quercetin, and epigallocatechin 3-gallate on mitogenic signaling and cell cycle regulators in human epidermoid carcinoma A431 cells. Nutr Cancer 2001; 39: 292-299.
Brandon-Warner E, Eheim AL, Foureau DM, Walling TL, Schrum LW, McKillop IH. Silibinin (Milk Thistle) potentiates ethanol-dependent hepatocellular carcinoma progression in male mice. Cancer Lett 2012; 326: 88-95
Chen CH, Huang TS, Wong CH, Hong CL, Tsai YH, Liang CC, et al. Synergistic anti-cancer effect of baicalein and silymarin on human hepatoma HepG2 Cells. Food Chem Toxicol 2009; 47: 638- 644.
Ciustea M, Ciustea G, inventors. Combination therapy and methods for treatment and prevention of hyperproliferative diseases. United States patent US 20130045179A1. 2013 Feb 21.
Cornblatt B, Cornblatt G, Bzhelyansky A, Henderson RW, inventors. Compositions comprising sulforaphane or a sulforaphane precursor and a milk thistle extract or powder. Taiwan patent TW201402129A. 2014 Jan 16.
Deep G, Agarwal R. Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther 2007; 6: 130-145.
. Fanoudi S, Alavi MS, Karimi G, Hosseinzadeh H. Milk thistle (Silybum marianum) as an antidote or a protective agent against natural or chemical toxicities: a review. Drug Chem Toxicol 2020; 43: 240-254.
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer 2021; 149: 778-789.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127: 2893-2917.
Frassová Z, Rudá-Kučerová J. Milk thistle (Silybum marianum) as a Supportive Phytotherapeutic Agent in Oncology. Klin Onkol 2017; 30: 426-432.
García-Maceira P, Mateo J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 2009; 28: 313-324.
Gorev V, Kostikov O, inventors. Three-component herbal formulation for the management of pre-diabetic and diabetic states, and liver diseases. Canada patent CA2983760A1. 2019 Apr
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
Juan Z, inventorA kind of Baoganleifufang and preparation method thereof. China patent CN110025686A. 2019 Jul 19.
Karbasforooshan H, Hosseini S, Elyasi S, Fani Pakdel A, Karimi G. Topical silymarin administration for prevention of acute radiodermatitis in breast cancer patients: A randomized, doubleblind,
. Kim SH, Choo GS, Yoo ES, Woo JS, Han SH, Lee JH, et al. Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells. Oncol Rep 2019; 42: 1904-1914.
Koo C-h, Lee Y-c, inventors. Composition for protecting hepatocyte containing silymarin and lipoic acid or its salts. South Korea patent KR100693613B1. 2007-03-14.
McCord JM, Myhill PR, inventors. Compositions for alleviating inflammation and oxidative stress in a mammal. United States patent US 9265808B2. 2016 Jan 23
Moezian G, Javadinia S, Sales S, Fanipakdel A, Elyasi S, Karimi G. Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial. J Oncol Pharm Pract 2022; 28: 827-835.
56. Moore A, Donahue T. Pancreatic Cancer. JAMA. 2019; 322: 1426.
Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and prevention of pancreatic cancer. Trends Cancer 2018; 4: 418- 428.
Murad H, inventor. Compositions and methods for treating dermatological disorders. United States. patent US 20020127256A1. 2002 Sep 12.
Neefjes EC, van der Vorst MJ, Blauwhoff-Buskermolen S, Verheul HM. Aiming for a better understanding and management of cancer-related fatigue. Oncologist 2013; 18: 1135-1143.
Nishisgori C. Current concept of photocarcinogenesis. Photochem Photobiol Sci 2015; 14: 1713-1721.
Program NT. Toxicology and carcinogenesis studies of milk thistle extract (CAS No. 84604-20-6) in F344/N rats and B6C3F1 mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 2011(565): 1-177.
Ramakrishnan G, Augustine TA, Jagan S, Vinodhkumar R, Devaki T. Effect of silymarin on N-nitrosodiethylamine induced hepatocarcinogenesis in rats. Exp Oncol 2007; 29: 39-44
Ramakrishnan G, Lo Muzio L, Elinos-Báez CM, Jagan S, Augustine TA, Kamaraj S, et al. Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells. Cell Prolif 2009; 42: 229-240.
Rangel JO, inventor. Prostate disorder(s) phyto-nutraceutical synergistic composition. United States patent US 20080260771A1. 2008 Oct 23.
Roy S, Deep G, Agarwal C, Agarwal R. Silibinin prevents ultraviolet B radiation-induced epidermal damages in JB6 cells and mouse skin in a p53-GADD45α-dependent manner. Carcinogenesis 2012; 33: 629-636.
Tooiserkani F, Hormati A, Moradi H, Ali asl F. A Glimpse of Silybum marianum from the perspective of Iranian traditional medicine and modern studies. Qom Univ Med Sci J 2019; 13: 78-86.
Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 2002; 8: 3512-3519.
Van Helvoort ALB, Norren KV, Hageman RJJ, Verwillegen WA, Lansink M, inventors. Anti-proliferative composition. European Patent Office. patent EP1448232B1. 2014 July 02.
Vidlar A, Vostalova J, Ulrichova J, Student V, Krajicek M, Vrbkova J, et al. The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy - a six month placebo-controlled double-blind clinical trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010; 154: 239-244.
Zhang X, Liu J, Zhang P, Dai L, Wu Z, Wang L, et al. Silibinin induces G1 arrest, apoptosis and JNK/SAPK upregulation in SW1990 human pancreatic cancer cells. Oncol Lett 2018; 15: 9868-9876.
Zi X, Grasso AW, Kung HJ, Agarwal R. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res 1998; 58: 1920-1929.
Emre M Isin, F Peter Guengerich complex reactions cataly by ctychrome P450 enzmyes Biochim Biophys Acta 2007 Mar;1770(3):314-29.
Ulrich M Zanger, Mattihas Schwab Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation Pharmacol Ther. 2013 Aprilİ138(1):103-41
S Beckmann-Knopp 1, S Rietbrock, R Weyhenmeyer, R H Böcker, K T Beckurts, W Lang, M Hunz, U Fuhr Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes Pharmacol Toxicol 2000
H W Leber, S Knauff Influence of silymarin on drug metabolizing enzymes in rat and man
Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, et al. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol 2016; 12: 1929-1946. 4. Anwar S, Madkor HR, Ahmed N, Wagih
Barros TMB, Lima APB, Almeida TC, da Silva GN. Inhibition of urinary bladder cancer cell proliferation by silibinin. Environ Mol Mutagen 2020; 61: 445-455.
Bhatia N, Agarwal C, Agarwal R. Differential responses of skin cancer-chemopreventive agents silibinin, quercetin, and epigallocatechin 3-gallate on mitogenic signaling and cell cycle regulators in human epidermoid carcinoma A431 cells. Nutr Cancer 2001; 39: 292-299.
Brandon-Warner E, Eheim AL, Foureau DM, Walling TL, Schrum LW, McKillop IH. Silibinin (Milk Thistle) potentiates ethanol-dependent hepatocellular carcinoma progression in male mice. Cancer Lett 2012; 326: 88-95
Chen CH, Huang TS, Wong CH, Hong CL, Tsai YH, Liang CC, et al. Synergistic anti-cancer effect of baicalein and silymarin on human hepatoma HepG2 Cells. Food Chem Toxicol 2009; 47: 638- 644.
Ciustea M, Ciustea G, inventors. Combination therapy and methods for treatment and prevention of hyperproliferative diseases. United States patent US 20130045179A1. 2013 Feb 21.
Cornblatt B, Cornblatt G, Bzhelyansky A, Henderson RW, inventors. Compositions comprising sulforaphane or a sulforaphane precursor and a milk thistle extract or powder. Taiwan patent TW201402129A. 2014 Jan 16.
Deep G, Agarwal R. Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther 2007; 6: 130-145.
. Fanoudi S, Alavi MS, Karimi G, Hosseinzadeh H. Milk thistle (Silybum marianum) as an antidote or a protective agent against natural or chemical toxicities: a review. Drug Chem Toxicol 2020; 43: 240-254.
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer 2021; 149: 778-789.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127: 2893-2917.
Frassová Z, Rudá-Kučerová J. Milk thistle (Silybum marianum) as a Supportive Phytotherapeutic Agent in Oncology. Klin Onkol 2017; 30: 426-432.
García-Maceira P, Mateo J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 2009; 28: 313-324.
Gorev V, Kostikov O, inventors. Three-component herbal formulation for the management of pre-diabetic and diabetic states, and liver diseases. Canada patent CA2983760A1. 2019 Apr
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
Juan Z, inventorA kind of Baoganleifufang and preparation method thereof. China patent CN110025686A. 2019 Jul 19.
Karbasforooshan H, Hosseini S, Elyasi S, Fani Pakdel A, Karimi G. Topical silymarin administration for prevention of acute radiodermatitis in breast cancer patients: A randomized, doubleblind,
. Kim SH, Choo GS, Yoo ES, Woo JS, Han SH, Lee JH, et al. Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells. Oncol Rep 2019; 42: 1904-1914.
Koo C-h, Lee Y-c, inventors. Composition for protecting hepatocyte containing silymarin and lipoic acid or its salts. South Korea patent KR100693613B1. 2007-03-14.
McCord JM, Myhill PR, inventors. Compositions for alleviating inflammation and oxidative stress in a mammal. United States patent US 9265808B2. 2016 Jan 23
Moezian G, Javadinia S, Sales S, Fanipakdel A, Elyasi S, Karimi G. Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial. J Oncol Pharm Pract 2022; 28: 827-835.
56. Moore A, Donahue T. Pancreatic Cancer. JAMA. 2019; 322: 1426.
Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and prevention of pancreatic cancer. Trends Cancer 2018; 4: 418- 428.
Murad H, inventor. Compositions and methods for treating dermatological disorders. United States. patent US 20020127256A1. 2002 Sep 12.
Neefjes EC, van der Vorst MJ, Blauwhoff-Buskermolen S, Verheul HM. Aiming for a better understanding and management of cancer-related fatigue. Oncologist 2013; 18: 1135-1143.
Nishisgori C. Current concept of photocarcinogenesis. Photochem Photobiol Sci 2015; 14: 1713-1721.
Program NT. Toxicology and carcinogenesis studies of milk thistle extract (CAS No. 84604-20-6) in F344/N rats and B6C3F1 mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 2011(565): 1-177.
Ramakrishnan G, Augustine TA, Jagan S, Vinodhkumar R, Devaki T. Effect of silymarin on N-nitrosodiethylamine induced hepatocarcinogenesis in rats. Exp Oncol 2007; 29: 39-44
Ramakrishnan G, Lo Muzio L, Elinos-Báez CM, Jagan S, Augustine TA, Kamaraj S, et al. Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells. Cell Prolif 2009; 42: 229-240.
Rangel JO, inventor. Prostate disorder(s) phyto-nutraceutical synergistic composition. United States patent US 20080260771A1. 2008 Oct 23.
Roy S, Deep G, Agarwal C, Agarwal R. Silibinin prevents ultraviolet B radiation-induced epidermal damages in JB6 cells and mouse skin in a p53-GADD45α-dependent manner. Carcinogenesis 2012; 33: 629-636.
Tooiserkani F, Hormati A, Moradi H, Ali asl F. A Glimpse of Silybum marianum from the perspective of Iranian traditional medicine and modern studies. Qom Univ Med Sci J 2019; 13: 78-86.
Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 2002; 8: 3512-3519.
Van Helvoort ALB, Norren KV, Hageman RJJ, Verwillegen WA, Lansink M, inventors. Anti-proliferative composition. European Patent Office. patent EP1448232B1. 2014 July 02.
Vidlar A, Vostalova J, Ulrichova J, Student V, Krajicek M, Vrbkova J, et al. The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy - a six month placebo-controlled double-blind clinical trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010; 154: 239-244.
Zhang X, Liu J, Zhang P, Dai L, Wu Z, Wang L, et al. Silibinin induces G1 arrest, apoptosis and JNK/SAPK upregulation in SW1990 human pancreatic cancer cells. Oncol Lett 2018; 15: 9868-9876.
Zi X, Grasso AW, Kung HJ, Agarwal R. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res 1998; 58: 1920-1929.
Emre M Isin, F Peter Guengerich complex reactions cataly by ctychrome P450 enzmyes Biochim Biophys Acta 2007 Mar;1770(3):314-29.
Ulrich M Zanger, Mattihas Schwab Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation Pharmacol Ther. 2013 Aprilİ138(1):103-41
S Beckmann-Knopp 1, S Rietbrock, R Weyhenmeyer, R H Böcker, K T Beckurts, W Lang, M Hunz, U Fuhr Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes Pharmacol Toxicol 2000
H W Leber, S Knauff Influence of silymarin on drug metabolizing enzymes in rat and man
Sayfalar
79-84
Yayınlanan
11 Mart 2024
Telif Hakkı (c) 2024 Akademisyen Yayınevi Kitap Portalı
Lisans
LisansNasıl Atıf Yapılır
1.
Serin Özel G. Deve Dikeni (Silybum Marianum). Içinde: Sakin A, editör. Kanser Hastalarının Başvurduğu Geleneksel ve Tamamlayıcı Tedaviler - Tıbbi Onkolog Gözü ile Bakış ve Onkolojik İlaçlarla Etkileşim [Internet]. Türkiye: Akademisyen Yayınevi Kitap DOI Portalı; 2024 [a.yer 13 Temmuz 2026]. ss. 79-84. Erişim adresi: https://www.omp35.books.akademisyen.net/index.php/akya/catalog/book/2380/chapter/13892
